Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting

References

• SEER Cancer Statistics [cited 2018 Aug 13]. Available from: https://seer.cancer.gov/statfacts/html/hodg.html.
   Google Scholar
• Boll B, Goergen H, Arndt N, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol. 2013;31(35):4431–4437.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–1514.
   PubMed Web of Science ®Google Scholar
• Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood. 2018;131(15):1689–1697.
   PubMed Web of Science ®Google Scholar
• von Keudell G, Younes A. Novel therapeutic agents for relapsed classical Hodgkin lymphoma. Br J Haematol. 2019;184(1):105–112.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Herrera AF, Beaven AW. Relapsed and refractory classical Hodgkin lymphoma: keeping pace with novel agents and new options for salvage therapy. Am Soc Clin Oncol Educ Book. 2019;39:477–486.
   PubMedGoogle Scholar
• Puig N, Pintilie M, Seshadri T, et al. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin’s lymphoma. Bone Marrow Transplant. 2011;46(10):1339–1344.
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Bartlett NL. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. Blood. 2018;131(15):1698–1703.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Transforming clinical research in the United States: challenges and opportunities: workshop summary. Washington (DC): National Academies Press (US); 2010.
   Google Scholar
• Unger JM, Cook E, Tai E, et al. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185–198.
   PubMedGoogle Scholar
• Mitchell AP, Kinlaw AC, Peacock-Hinton S, et al. Use of high-cost cancer treatments in academic and nonacademic practice. Oncologist. 2020;25(1):46–54.
   PubMed Web of Science ®Google Scholar
• Differences in community-based providers and academically-based providers [cited 2020 Mar 4]. Available from: https://www.primeoncology.org/primetimes/community-vs-academic-providers/.
   Google Scholar
• Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16(3):37–41.
   PubMedGoogle Scholar
• Field TS, Cernieux J, Buist D, et al. Retention of enrollees following a cancer diagnosis within health maintenance organizations in the Cancer Research Network. J Natl Cancer Inst. 2004;96(2):148–152.
   PubMedGoogle Scholar
• Chao C, Chiu V, Mueller LA, et al. Exploring the feasibility of establishing a retrospective cohort of survivors of adolescent and young adult cancer to study long-term health outcomes in an integrated managed care environment. J Adolesc Young Adult Oncol. 2013;2(2):59–65.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Engert A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2020;136(26):2987–2993.
   PubMed Web of Science ®Google Scholar
• Chao CR, Xu L, Cannizzaro N, et al. The development and validation of an Electronic Health Record (EHR)-based algorithm for identifying treatment failure in newly diagnosed Hodgkin lymphoma (HL) treated in a US community oncology setting. Blood. 2018;132(Supplement 1):2261–2261.
   Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–1636.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Horning SJ. Primary refractory Hodgkin’s disease. Ann Oncol. 1998;9 (Suppl 5):S97–S101.
   PubMedGoogle Scholar
• Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–4206.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684–691.
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634–4642.
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–4554.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Shrestha R, Cook NM. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: analysis of the National Cancer Data Base. Cancer. 2015;121(19):3472–3480.
   PubMed Web of Science ®Google Scholar
• Hapgood G, Zheng Y, Sehn LH, et al. Evaluation of the risk of relapse in classical Hodgkin Lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol. 2016;34(21):2493–2500.
   PubMed Web of Science ®Google Scholar